Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718425 | 0.86 | SLC6A1 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL25368480 | 0.82 | — | — | |
| SCHEMBL20875297 | 0.82 | — | — | |
| SCHEMBL22712720 | 0.82 | — | — | |
| SCHEMBL22491873 | 0.75 | BRD4 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL18493226 | 0.75 | BRD4 (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL21063492 | 0.74 | — | — | |
| SCHEMBL28488982 | 0.74 | SLC6A1 (0.44) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL3068424 | 0.73 | HDAC1 (0.33) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL21063499 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561256-A | Crystal form of biphenyl derivative inhibitor and preparation method thereof | 上海翰森生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-113348170-B | Biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-115536657-A | Salt of biphenyl derivative inhibitor, crystal form and preparation method thereof | 上海翰森生物医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154780-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | S1PR1, S1PR5, S1PR2 | SLC6A1 2077/4885GABRA5 620/4885GABRB2 955/4885 |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | SLC6A1 2085/4885GABRA5 608/4885GABRB2 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.